Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study
Clinical and Experimental Dermatology · 2023
DOI: 10.1093/ced/llad020 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2023. Verfasst von Parul Kamboj und 6 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Dermatology, Venereology and Leprology. Hauptthemen laut MEDLINE: Metformin, Insulin Resistance, Polycystic Ovary Syndrome, Acne Vulgaris. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: PGIMER, Indian Council of Medical Research.
Abstract (Originalsprache)
Background
Acne vulgaris is associated with insulin resistance and elevated insulin-like growth factor-1 (IGF-1). Metformin is commonly used for treatment of acne in patients with polycystic ovarian syndrome (PCOS). However, the benefits of metformin in patients with acne in general are not well established.
Aim
To study the effectiveness of metformin treatment in patients with acne but who do not have PCOS and to understand the mechanisms of action of metformin in acne not related to PCOS.
Method
In this observational study, 30 patients with clinically confirmed acne vulgaris were treated with metformin (1000 mg daily) for 3 months without any other topical or systemic active intervention for their acne. The effect of metformin at the clinical, hormonal and genetic level was assessed.
Results
Metformin monotherapy significantly (P < 0.001) decreased the global acne grading score for acne followed by a marginal increase in insulin; with a significant (P = 0.03) increase in insulin-like growth factor-1 (IGF-1). A significant (P < 0.001) decrease in free androgen index resulting from a significant (P < 0.001) increase in sex hormone-binding globulin (SHBG) with decrease in testosterone was observed. Homeostasis model assessment insulin resistance (HOMA-IR) was not significantly changed. Forkhead box protein O1 (FOXO1) expression was significantly (P = 0.006) downregulated with metformin treatment at the mRNA level without any significant changes at protein level. Expression of lipogenic genes, namely HMGCR, SQLE and ACSL5 (P = 0.001, P = 0.03, P = 0.03, respectively) were also downregulated.
Conclusion
Metformin monotherapy led to significant clinical improvement in acne, possibly by reducing testosterone, inhibiting FOXO1 and reducing lipid synthesis by decreasing the expression of lipogenic genes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Departments of Dermatology, Venereology and Leprology.
- Endocrinology.
- Histopathology.
- Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Förderung
- PGIMER
- Indian Council of Medical Research
Zitieren
APA
Kamboj, P., Kaushik, A., Handa, S., Dutta, P., Saikia, U. N., Pal, A., & De, D. (2023). Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad020
Vancouver
Kamboj P, Kaushik A, Handa S, Dutta P, Saikia UN, Pal A, et al. Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study. Clinical and Experimental Dermatology. 2023. doi:10.1093/ced/llad020
BibTeX
@article{Kamboj2023,
author = {Kamboj, Parul and Kaushik, Akanksha and Handa, Sanjeev and Dutta, Pinaki and Saikia, Uma Nahar and Pal, Arnab and De, Dipankar},
title = {Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study},
journal = {Clinical and Experimental Dermatology},
year = {2023},
doi = {10.1093/ced/llad020}
}
EUVIMED